Botswana vs Vietnam: Average cost of drugs for extensively drug-resistant tuberculosis
Botswana
900 constant 2022 US$
in 2024
Vietnam
807 constant 2022 US$
in 2024
Botswana rank
44th
Vietnam rank
46th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Botswana
- Vietnam
How they compare
Botswana currently reports 900 constant 2022 US$ against 807 constant 2022 US$ in Vietnam, a difference of 93 constant 2022 US$.
That makes Botswana's figure about 1.1 times Vietnam's.
The two have swapped places 2 times across 5 shared years of data; in 2017 it was Botswana ahead.
Botswana ranks 44th and Vietnam ranks 46th of 56 countries.
Across the 2 decades both report, Botswana averaged higher in 1 and Vietnam in 1.
Head to head by decade
| Decade | Botswana | Vietnam | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 7,178 constant 2022 US$ | 4,643 constant 2022 US$ | 2,535 constant 2022 US$ | Botswana |
| 2020s | 1,200 constant 2022 US$ | 2,725 constant 2022 US$ | 1,525 constant 2022 US$ | Vietnam |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Botswana or Vietnam?
- Botswana, at 900 constant 2022 US$ against 807 constant 2022 US$ in Vietnam as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Botswana and Vietnam?
- 93 constant 2022 US$, with Botswana ahead.
- How many years of comparable data are there for Botswana and Vietnam?
- 5 years are reported by both, from 2017 to 2024.
- How do Botswana and Vietnam rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Botswana ranks 44th and Vietnam ranks 46th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.